Edit Content

Welcome to the Innovative Psychiatric

Get Started

The Evaluation Process

Fill Out Initial Questionnaire

Provide medical history, symptoms, and past treatments.

Psychiatric
Evaluation

Clinician confirms diagnosis for Spravato suitability.

Develop Personalized Treatment Plan

Collaborate on dosage and complementary therapies.

 Insurance & Financial Coordination

Assistance with coverage, costs, and payment plans for various providers.

Patient
Education

Understand the Spravato process, side effects, and safety measures.

Treatment Commencement

Begin Spravato sessions at our clinic with continuous monitoring and adjustments.

What we offer

Treating Depression
Over 21 million Americans are affected by Major Depressive Disorder. Regrettably, nearly half of those who undergo treatment with antidepressant medications do not experience a sufficient response. The FDA defines Treatment-Resistant Depression (TRD) as a condition where patients fail to adequately respond to two distinct antidepressants of appropriate dosage and duration.
Contact us
The Treatment
SPRAVATO is a nasal spray containing Esketamine for treating depression. Patients self-administer the spray under a healthcare professional's supervision, who monitors them for 2 hours per FDA guidelines. The treatment has two phases: Initiation (twice a week for four weeks) and Maintenance (weekly or biweekly). Our patient pods offer a comfortable setting with HD TVs and reclining chairs. Studies show SPRAVATO provides positive results without long-term serious side effects, abuse potential, or significant weight gain or sexual side effects.
Contact us

Contact Us

    SPRAVATO – In 2019, the FDA granted approval for Spravato (Esketamine) to treat Treatment Resistant Depression (TRD). Initially approved as an anesthetic agent in 1970, ketamine was later discovered to have a rapid and potent antidepressant effect when administered intravenously. Notably, Spravato is an intranasal formulation that is patient-administered under supervision. It became the first and only form of ketamine approved for use in treating depression. To find out more, visit:

    Spravato
    Specializing in Spravato, a breakthrough treatment for treatment-resistant depression
    Useful Links
    Office Hour
    • Monday – Friday
    • 9:00 AM – 5:00 PM
    • Saturday – Sunday
    • Closed
    Get In Touch

    © 2025 Innovative Psychiatric Services. All Rights Reserved